{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"61.400","rs_stock_flag":false,"fiscal_year_end":"","hist_closedate":"","replication_method":null,"amt_os":"154,327,250","primaryexch":"香港交易所","ric":"2659.HK","product_subtype":null,"db_updatetime":"2025年12月10日09:36","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BWH4LW7","am":"306.97","iv":"","ew_strike":"","as":"58.000","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"57.950","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-12-10 01:36:29.0","lo52":"","shares_issued_date":"2025年12月10日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"劉彥君","underlying_ric":"2659.HK","hi52":"","issuer_name":"上海寶濟藥業股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年12月10日10:23","aum_date":"","lo":"56.000","mkt_cap":"8.95","f_aum_hkd":null,"ew_sub_per_to":"","ls":"58.000","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"0","aum":"","issued_shares_class_B":null,"vo":"5.60","secondary_listing_flag":false,"listing_date":"2025年12月10日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"上海寶濟藥業股份有限公司 - B - H股","nm_s":"寶濟藥業－Ｂ","sym":"2659","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"上海寶濟藥業股份有限公司是一家主要從事藥品研發業務的中國公司。該公司利用合成生物技術開發及提供重組生物藥物，專注於攻克治療選擇有限且藥物製造工藝複雜的目標病症。該公司聚焦四大領域，包括大容量皮下給藥，抗體介導的自身免疫性疾病，輔助生殖藥物及以重組生物製藥取代傳統生化製品的變革性產品。該公司的核心產品包括SJ02（晟诺娃），是一種長效重組人卵泡刺激素羧基末端肽融合蛋白（FSH-CTP）, KJ017，是一種重組人透明質酸酶，及KJ103，是一種創新重組免疫球蛋白G(IgG)降解酶。","op":"60.500","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"藥品","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國上海<br/>寶山區<br/>羅新路28號","pc":"0.00","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"","isin":"CNE100007B92","moneyness":""}},"qid":"1765334290535"}
